Dermatology Flashcards
What are 2 topical corticosteroids classified as “Very Potent” in Australian Classifications
Betamethasone dipropionate 0.05% in optimised ointment
Clobetasol propionate 0.05% ointment
What are 3 topical corticosteroids classified as “Potent” in Australian Classifications
Betamethasone dipropionate 0.05% in standard ointment
Betamethasone valerate 0.1% ointment
Mometasone furoate 0.1% ointment/cream
What are 5 topical corticosteroids classified as “moderate” in Australia
Betamethasone dipropionate 0.05% Cream/lotion
Betamethasone valerate 0.05% ointment and vream
Triamcinolone acetonide 0.1% cream
Methylprednisolone aceponate 0.1% ointment/cream/lotion
Clobetasone 0.05% cream
What are 2 topical corticosteroids classified as “Low potency” in Australia
Hydrocortisone or hydrocortisone acetate 0.5%, 1% (ointment/cream/lotion)
Desonide 0.05% (ointment/cream/lotion)
Features of different forms of topical corticosteroids
Ointments:
- improve drug absorption due to occluding skin and enhancing hydration
- greasy, difficult to spread, poor adherence
Creams:
- combo of 1 or more non-mixable liquids + emulsifying agent
- less greasy, easy to spread
- washable in water
Lotions:
- insoluble preparations dispersed into liquid
- may need shaking to prepare for use
- easy to apply
- can cover extensive areas
- preferred for children, and hairy skin
Local adverse effects of topical steroids
- Atrophy (skin transparency, brightness, telangiectasia, striae, easy bruising)
- Rosacea, acne or perioral dermatitis when used on face
Less common:
Hypopigmentation, delayed wound healing, glaucoma (when used around eye), rebound effect when ceased, loss of clinical improvement after period of use, masking or stimulation of cutaneous infections e.g. tinea incognito
Systemic adverse effects of topical corticosteroids
Uncommon, associated with prolonged use of high potency steroids in large or denuded areas
- reversible HPA axis suppression
- Addisonian crisis on ceasing
- Cushing’s syndrome
- DM
- hyperglycaemia
Diseases likely to be highly responsive to topical corticosteroids
Inflammatory conditions on thin skin;
e. g.
- intertriginous psoriasis
- Children’s atopic dermatitis
- other intertrigos
Diseases likely to be moderately responsive to topical corticosteroids
Psoriasis
Adult atopic dermatitis
Nummular eczema
Diseases likely to be least responsive to topical corticosteroids
Chronic, hyperkeratotis, lichenified or indurated lesions. e.g.
- palmo-plantar psoriasis
- lichen planus
- lichen simplex chronicus
Sites and absorption of topical corticosteroids
Palms, soles - poor absorption (0.1-0.8%)
Forearms - poor (1%)
Scalp and intertriginous areas - moderate (4%)
Face - moderate (10%)
Scrotum and eyelids - very high (40%)
Choice of topical corticosteroid vehicle for disesase
Ointments: thick, fissured lichenified lesions SHOULD NOT BE USED IN FLEXURAL OR INTERTRIGINOUS areas
Creams: most areas except scalp/hairy skin
Lotions: extensive areas
Solutions, gels, sprays, foams: scalp and hairy skin
Maximum doses of topical corticosteroids in adults
Potent: 45g/week
Moderately potent: 100g/week
Maximum duration of topical steroids
Face: 2 weeks
Rest of body: 3-4 weeks
Adjunctive treatments with topical corticosteroids
Skin care to improve skin’s overall integrity and improve clinical outcome
- soap-free cleansers
- moisturisers
Focused history for skin check
Presenting complaint - new, changing or concerned lesions
Occupation, sun exposure and sun protection
Personal and family history of NMSC and melanoma
General medical history (current and past)
Drug history (esp. anticoagulants, immunosuppressants)
High risk patients for skin cancer and how frequently should have skin check
3 monthly self examination, 12 monthly skin check
- red hair
- Type I skin >45y
- type II skin >65y
- Family history of melanoma in first degree relative in patients >15y
- > 100 naevi (>10 atypical)
- past history of melanoma
- Past history of NMSC or >20 solar keratoses
Medium risk patients for skin cancer and recommended frequency of skin checks
3-6 monthly self-check, 2-5 yearly skin check with doctor
- Blue eyes
- Type 1 skin 25-45y
- Type II skin 45-65y
- Type 3 skin >65
- Family history of NMSC
- Past history of solar keratosis
- multiple previous episodes of sunburn
Low risk patients for skin cancer and recommended frequency of skin checks
Annual self-check, one-off skin check with doctor for assessment of risk and advice regarding skin care
- Type I skin <25y
- Type II skin <45y
- Type III skin <65y
- Type 4 & 5 skin
Cure rate for solar keratoses with cryotherapy
86-99%
Contraindications for cryotherapy
- Lesions with poorly defined margins
- Lesions >2cm diameter
- Lesions >3mm deep
- lesions tethered to underlying structures
- lesions on ala nasi, eyelids, nasolabial fold and pre-auricular skin
- recurrent lesions
- agammaglobuliaemia cryoglobulinaemia
- blood dyscrasias of unknown origin
- cold urticaria
- Raynaud’s disease
- Pyoderma gangrenosum
- collagen and autoimmune disease
- avoid if histology is uncertain
- can be problematic for patients with Fitzpatrick III-V due to post inflammatory hyperpigmentation and hypopigmentation
- risk of alopecia on hair bearing skin e.g. beard area
Recommended technique for cryotherapy of solar keratosis
1x freeze cycle of 15 seconds, 1mm margin
Expected results after cryotherapy with liquid nitrogen
Day 1: red, swollen, blister may develop and may fill with blood - best to leave alone
Days 2-3: Treated area becomes weepy, leave skin open to air if mild and wash with soap and water, if excessive cover with dressing or topical antiseptic
Days 3-4: Area should stop weeping and form scab which usually spontaneously falls off within a week
Should then heal without a scar - may be slightly darker or lighter skin temporarily (may be permanent)
Indications to biopsy a clinical actinic keratosis
"Thickness" on palpation Pain - particularly on lateral pressure Bleeding Rapid growth Failure of standard topical treatments